Polyangitis
Drug research and approvals for polyangitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 76 studies of polyangitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.
- Recruiting worldwide: 76
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 76 recruiting on ClinicalTrials.gov ↗- FT839 in Autoimmune DiseasesNCT07800871 · Phase 1 / Phase 2 · Fate Therapeutics · starts Oct 1, 2026
- Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated GlomerulonephritisNCT07746180 · Phase 2 · Chinese PLA General Hospital · starts Aug 21, 2026
- Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit…NCT07444567 · Phase 3 · AstraZeneca · starts Jul 24, 2026
- TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With PolyangiitisNCT07176546 · Phase 2 / Phase 3 · Robert Spiera, MD · starts May 22, 2026
- CD19/BCMA UCAR-T for B Cell-Related Autoimmune DiseaseNCT07586267 · Early Phase 1 · The Children's Hospital of Zhejiang University School of Medicine · starts May 8, 2026
- Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseNCT07507201 · Early Phase 1 · The Children's Hospital of Zhejiang University School of Medicine · starts Apr 1, 2026
- MTS109 in Patients With Refractory Autoimmune DiseasesNCT07526350 · Early Phase 1 · Shanghai Changzheng Hospital · starts Mar 24, 2026
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic DiseasesNCT07087912 · Phase 4 · University of Sao Paulo General Hospital · starts Mar 16, 2026
- Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of…NCT07246096 · Early Phase 1 · Changhai Hospital · starts Feb 20, 2026
- Benralizumab Effectiveness in EGPANCT07815886 · Not reported · European EGPA Study Group · starts Feb 11, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Feb 13, 2025 | Safe effective therapy with low-dose glucocorticoid in anca-associated vasculitis (safe-low) trialCyclophosphamide / prednisone | Ottawa Hospital Research Institute | Ongoing |
| Apr 24, 2024 | A randomized, controlled study to evaluate lnp023 (iptacopan) in patients with active anca-associated vasculitisIptacopan (LNP023) | Novartis Pharmaceuticals | Closed |
| Jun 2, 2022 | 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab…Depemokimab | GSK | Closed |
| Aug 21, 2019 | A randomised, double-blind, active-controlled 52-week study with an open-label extension to evaluate the efficacy and safety of benralizumab compared to…Benralizumab (MEDI-563) | AstraZeneca Pharmaceuticals | Ongoing |
| May 7, 2015 | "abatacept (ctla4-ig) for the treatment of relapsing, non-severe, granulomatosis with polyangiitis (wegener's) (abrogate)."Orencia | University Of South Florida | Ongoing |
| Mar 9, 2015 | Mepolizumab long-term access programme for subjects who participated in study mea115921 (placebo-controlled study of mepolizumab in the treatment of…SB240563 (mepolizumab) | GSK | Closed |
| Nov 27, 2014 | A phase IIa, international, multicenter, open-label, uncontrolled study to evaluate the safety and pharmacokinetics of 4x 375 mg/m2 intravenous rituximab in…Rituxan | Roche | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA